US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Elicio Therapeutics Inc.

< Previous 1 2 Next >
News headline image
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Added to Russell 2000® and Russell 3000® Indexes
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Announces Publication in Peer-Reviewed Journal Science Advances Highlighting Potent and Durable Immune Responses Driven by Company’s AMP-DNA Adjuvant Technology
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics to Present at the Bank of America Healthcare Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Antigen Spreading to Patient-Specific Neoantigens Beyond mKRAS in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Appoints Veteran CMC and Technical Operations Executive Marc J. Wolfgang as Chief Technology Officer
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Robust, Cytolytic mKRAS-Specific T Cell Responses Across Diverse Patient HLA in Ongoing Phase 2 AMPLIFY-7P Trial of ELI-002 7P and New ELI-004 Preclinical Data at SITC
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics to Present Clinical and Preclinical Data at the SITC 2025 Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Robust T cell Responses Across Diverse HLA backgrounds in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Announces Investigator-Initiated Phase 1 Trial to be Conducted by Memorial Sloan Kettering Cancer Center and funded by The Lustgarten Foundation for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Reports ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable Patients in Ongoing Phase 2 AMPLIFY-7P Trial
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
News headline image
Elicio Therapeutics Announces Publication of ELI-002 Updated AMPLIFY-201 Phase 1 Follow-up Data in Nature Medicine for Minimal Residual Disease (“MRD”) Positive, Adjuvant-Stage Patients
From Elicio Therapeutics Inc.
Via GlobeNewswire
Tickers ELTX
< Previous 1 2 Next >